Home Featured Page 184

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Numinus Unveils New Logo and Brand Identity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking...

Digging Up Druggable Targets: Psilocybin Efficacy in a Model of OCD

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation...

Incannex to Present at the H.C. Wainwright First Annual Mental Health...

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Numinus Unveils New Logo and Brand Identity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking...

Digging Up Druggable Targets: Psilocybin Efficacy in a Model of OCD

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation...

Incannex to Present at the H.C. Wainwright First Annual Mental Health...

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY